Blog

How Patient Reported Outcomes Can Guide Trial Eligibility – ESMO

ESMO/LinkedIn

Jul 19, 2025, 14:29

How Patient Reported Outcomes Can Guide Trial Eligibility – ESMO

European Society for Medical Oncology shared a post on LinkedIn:

“In the era of Precision Medicine, waiting lists for alteration-matched studies are one of the key challenges in Early Drug Development.

Findings presented at ESMOTATAsia25 highlighted that Patient Reported Outcomes (PROs) may be a valid tool to select fitness for inclusion in a phase I Clinical Trial after 3 months.

Also presented were recommendations from the OPTIMISE-ROR project, which provides foundational guidance for triallists to systematically integrate PROs into dose-finding oncology trials.

Read the full commentary in the ESMO Daily Reporter.”

More posts featuring ESMO on OncoDaily.

cancer Early Drug Development ESMO ESMO Daily Reporter ESMOTATAsia25 European Society for Medical Oncology OncoDaily Oncology OPTIMISE-ROR project Precision Medicine

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Kevin Conroy: Oncodetect is Now Covered by Medicare in Stage IV Colorectal Cancer